PCM
ESPR

Poehling Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Poehling Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-300
Closed -$12K – 159
2018
Q2 		$12K Hold
300
– – 0.01% 218
2018
Q1 		$22K Hold
300
– – 0.02% 187
2017
Q4 		$20K Buy
+300
New +$16.2K 0.02% 184

Other funds holding ESPR

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Poehling Capital Management's ESPR Position: Q3 2018 in Review

Poehling Capital Management sold out of Esperion Therapeutics (ESPR) in Q3 2018, closing a stake of 300 shares — an estimated $12K sold.

Poehling Capital Management first reported a position in ESPR in Q4 2017 and held it in 3 quarters. The position peaked at $22K in Q1 2018. 155 funds tracked by Wall St. Rank hold ESPR as of Q3 2018.

  • Poehling Capital Management reported no remaining Esperion Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Poehling Capital Management sold 300 Esperion Therapeutics shares in Q3 2018, an estimated $12K.
  • Poehling Capital Management first reported a position in Esperion Therapeutics in Q4 2017 and held it in 3 quarters.
  • Poehling Capital Management's Esperion Therapeutics position peaked at $22K in Q1 2018.
  • 155 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2018.

Based on Poehling Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.